Expert Theater

These non-CME presentations can add to your educational experience. Learn about company products and services that can help you in your practice. Both in-person and virtual sessions will take place during conference breaks. In-person sessions are limited to 125 participants, and food and beverages will be served. Make plans now to visit one or more of these daily presentations.

In-person expert theaters will take place in the Exhibit Hall.

Expert theaters being hosted on the ACEP21 Conference Platform are listed below the in-person sessions.

All times are EDT. Schedule is subject to change. 

IN-PERSON EXPERT THEATERS


Monday, October 25

11:30 am - 12:15 pm | Expert Theater 1

The Burden of Life Threatening Bleeds and the Urgency to Treat

Presented by Alexion Pharmaceuticals, Inc.

Speakers: James M. Williams, MS, DO, FACEP

ANDEXXA Promotional Program Overview

  • Burden of life-threatening bleeds related to FXa inhibitors
  • Review the indication, mechanism of action, efficacy, and safety of ANDEXXA for the reversal of FXa inhibitors apixaban or rivaroxaban in patients with life-threatening bleeds

11:30 am - 12:15 pm | Expert Theater 2

Antivenom Use in the Alpha-Galaxy

Presented by BTG Specialty Pharmaceuticals

Speaker: Spencer Greene, MD, MS, FACEP, FACMT, FAACT, FAAEM

Dr. Greene will discuss pitfalls in the management of North American pit viper envenomation. In this lecture, you will learn how to avoid common mistakes when managing snakebite patients and gain a better understanding of the evidence to support best practices. Topics will include an overview of the medical management of envenomation with an emphasis on regional differences that may impact treatment decisions. 

2:30 pm - 3:15 pm | Expert Theater 1

Non-convulsive Seizures and the Need for Rapid Brain Monitoring in the Emergency Department

Presented by Ceribell, Inc.

Speakers: Diku Mandavia, MD and Laleh Gharahbaghian, MD

Up to 1/3 of high-risk critical patients have non-convulsive seizures that can cause long-term cognitive disability and morbidity. Time to treatment is critical for optimal outcomes as prolonged seizures are associated with high morbidity and mortality and thus it is imperative that emergency physicians detect and treat early. Ceribell is a point-of-care brain monitor that enables ED clinicians to detect these silent seizures within minutes upon suspicion.

2:30 pm - 3:15 pm | Expert Theater 2

The Cutting Edge of Brain Injury Evaluation in the ED: Using Biomarkers for Objective Assessment of Suspected Mild Traumatic Brain Injury (mTBI)

Presented by Abbott

Speakers: Jesse Pines, MD and Paul Jarvis, MD

The current approach to Traumatic brain injury (TBI) evaluation has limitations. Join experts for an update about brain injury biomarkers and how UCH-L1 and GFAP have emerged as promising biomarkers.


Tuesday, October 26

11:30 am - 12:15 pm | Expert Theater 1

Immune-Related Adverse Events Caused by Immune Checkpoint Inhibition

Presented by Bristol-Myers Squibb Company

Speaker: Stephen Ford, PharmD, BCOP

This presentation will provide an introduction to the immune system and immuno-oncology and educate on some of the immune-related adverse events (irAEs) that can result from immune checkpoint inhibition. We will also review signs and symptoms of select irAEs and provide a summary of general management principles for select irAEs.

11:30 am - 12:15 pm | Expert Theater 2

Managing the Coagulopathy of Hospitalized COVID-19 Patients

Presented by Sanofi US

Speaker:  Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC

COVID-19 pandemic continues to be a challenge for HCPs. With rising infection rates throughout several states in the US, some states are seeing significant hospitalization and ICU admissions. There is also a concern that SARS-Cov-2 infection may prevail to next year.  One of the severe complications of COVID-19 is thromboembolism which resulted from an increased coagulopathy, contributing to mortality for those hospitalized with acute and/or critical COVID-19 illness.  The lecture will provide a quick update on the published International and US guidance and the latest evidence on the use of thromboprophylaxis in hospitalized COVID-19 patients.

2:30 pm - 3:15 pm | Expert Theater 1

Rapid Objective Evaluation of Mild Head Injury in the ED Using EEG-Based Biomarkers

Preseented by BrainScope Company, Inc.

Speakers: Marleine S. Clay, MD, FACEP

Computerized Tomography (CT) scan remains the standard of care for evaluating traumatic brain injury (TBI) in the Emergency Department (ED). Studies have reported that over 85% of head-injured patients receive CT scans in the ED, yet 91% of these scans are found to be negative. Not only does this practice expose these patients unnecessarily to radiation, but it also increases the use of this resource and lengthens throughput times in the ED. In addition, patients found to be CT negative are most often discharged without evaluation or referral for concussion. There is a great need for the integration of reliable, objective predictors of intracranial injury in the mild head injured population.

Join Dr. Marleine Clay as she examines the current challenges facing EDs today in assessing the mild head injured population and the impact BrainScope’s EEG-based biomarkers can have on improving care pathways and patient satisfaction. Prior to implementing BrainScope at INOVA Fairfax, Dr. Clay conducted a study to determine utilization, staff assessment, and patient experience of the BrainScope technology in daily use. Dr. Clay will review the results of the INOVA trial, which were overwhelmingly positive.


Wednesday, October 27

11:30 am - 12:15 pm | Expert Theater 1

Clinical Insights in VTE: Treatment & Risk Reduction through Prophylaxis

Presented by Janssen Pharmaceuticals

Speaker: Stanley C. Thompson, MD

This lecture will discuss venous thromboembolism (VTE) prophylaxis, as well as treatment options for patients with deep vein thrombosis and/or pulmonary embolism, and how these treatment options may reduce the risk of recurrent thrombotic events.

11:30 am - 12:15 pm | Expert Theater 2

Spotlight on Acute Agitation Associated with Schizophrenia and Bipolar Disorders: What Can Be Improved?

Presented by BioXcel Therapeutics

Speaker: Leslie Zun, MD

Acute agitation is a behavioral emergency that is very common in patients with schizophrenia and bipolar disorders; it presents along a spectrum from mild to severe, with most behavioral signs consistent with mild to moderate agitation. However, if escalated, agitation poses a potential safety risk to staff and patients. This program will take the audience through an in-depth look into acute agitation as it presents in the acute care setting, discuss current practice, and use a real-world patient case to illustrate de-escalation and guideline-recommended management approaches for agitation. Attendees can look forward to a highly interactive presentation, led by an industry expert, and a Q&A session following the presentation.

2:30 pm - 3:15 pm | Expert Theater 1

COVID-19 and Beyond: syndromic respiratory diagnostics in the ED

Presented by BioFire Diagnostics, LLC

Speakers:  Sean-Xavier Neath, MD, PhD

With the evolving epidemiology of respiratory pathogens more uncertain than ever, rapid and comprehensive pathogen ID is at the forefront of emergency medicine.  Distinguishing between SARS-CoV-2, influenza, and even adenovirus or parainfluenza accurately and quickly is now possible with a multiplex PCR panel like the BioFire® Respiratory 2.1 (RP2.1) Panel. In this workshop, learn how implementing a syndromic approach to diagnosing respiratory tract infections can help inform patient management decisions in the era of COVID-19

2:30 pm - 3:15 pm | Expert Theater 2

Appropriate Patients for Neutralizing Monoclonal Antibodies in the Management of COVID-19 Before Hospitalization

Presented by Regeneron

Speaker: Suraj Saggar, DO

The COVID-19 pandemic continues to affect patients around the world, highlighting the need for treatments to combat it. Monoclonal antibodies against SARS-CoV-2 have been shown to be an effective regimen in the fight against COVID-19 and have received emergency use authorization by the FDA. This presentation will discuss the COVID-19 spectrum of disease, the mechanism of action and clinical experience of a COVID-19 monoclonal antibody therapeutic, as well as provide potential guidance for where neutralizing monoclonal antibodies can fit into the management paradigm for COVID-19.


Virtual ACEP21 Expert Theater Schedule

Monday, October 25

11:30 am - 12:15 pm

Spotlight on Acute Agitation Associated with Schizophrenia and Bipolar Disorders: What Can Be Improved?

Presented by BioXcel Therapeutics

Speaker:  Leslie Zun, MD

Acute agitation is a behavioral emergency that is very common in patients with schizophrenia and bipolar disorders; it presents along a spectrum from mild to severe, with most behavioral signs consistent with mild to moderate agitation. However, if escalated, agitation poses a potential safety risk to staff and patients. This program will take the audience through an in-depth look into acute agitation as it presents in the acute care setting, discuss current practice, and use a real-world patient case to illustrate de-escalation and guideline-recommended management approaches for agitation. Attendees can look forward to a highly interactive presentation, led by an industry expert, and a Q&A session following the presentation.

2:30 pm - 3:15 pm

The Cutting Edge of Brain Injury Evaluation in the ED: Using Biomarkers for Objective Assessment of Suspected Mild Traumatic Brain Injury (mTBI)

Presented by Abbott POC

Speakers: Jesse Pines, MD and Paul Jarvis, MD

The current approach to Traumatic brain injury (TBI) evaluation has limitations. Join experts for an update about brain injury biomarkers and how UCH-L1 and GFAP have emerged as promising biomarkers.

2:30 pm - 3:15 pm

The Future of the ED is Here: The Digital Transformation of Patient Safety

Presented by Nuance Communications

Speakers: Dan Sullivan, MD, JD, FACEP and Reid Conant, MD, FACEP

Diagnostic errors account for nearly 75% of all serious harm to patients. Learn how you can drive patient safety in the ED through technology, addressing diagnostic error and poor documentation.


Tuesday, October 26

11:30 am - 12:15 pm

Unlocking the CBC A Role for Monocyte Distribution Width in ED-Based Sepsis Diagnosis

Presented by Beckman Coulter, Inc.

Speaker: Jeremiah Stephen Hinson, MD, PhD and Nima Sarani, MD

Drs. Hinson and Sarani introduce the hematological parameter Monocyte Distribution Width and discuss the latest evidence how it’s being used as an aid in severe infection and risk of sepsis in the ED.

11:30 am - 12:15 pm

Clinical Insights in VTE: Treatment & Risk Reduction through Prophylaxis

Presented by Janssen Pharmaceuticals

Speaker: James Neuenschwander MD, FACEP, FASAM

This lecture will discuss venous thromboembolism (VTE) prophylaxis, as well as treatment options for patients with deep vein thrombosis and/or pulmonary embolism, and how these treatment options may reduce the risk of recurrent thrombotic events.

2:30 pm - 3:15 pm

Non-convulsive Seizures and the Need for Rapid Brain Monitoring in the Emergency Department

Presented by Ceribell, Inc.

Speakers: Diku Mandavia, MD and Laleh Gharahbaghian, MD

Up to 1/3 of high-risk critical patients have non-convulsive seizures that can cause long-term cognitive disability and morbidity. Time to treatment is critical for optimal outcomes as prolonged seizures are associated with high morbidity and mortality and thus it is imperative that emergency physicians detect and treat early. Ceribell is a point-of-care brain monitor that enables ED clinicians to detect these silent seizures within minutes upon suspicion.

2:30 pm - 3:15 pm

Clinical Practice Guideline for Nasal High Flow

Presented by Fisher & Paykel Heathcare

Speaker: Casey D. Bryant, MD

This presentation will review the ESICM Clinical Practice Guidelines (Rochwerg, 2020) recently published in Intensive Care Medicine, regarding the use of Nasal High Flow in adult patients. It will take a broad look at the evidence base supporting Nasal High Flow for a number of common clinical scenarios including hypoxemia, intubation, and post-extubation.  It will review the recommendations for use of Nasal High Flow and the associated rationale supporting these recommendations. 


WEDNESDAY, OCTOBER 27

11:30 am - 12:15 pm

Antivenom Use in the Alpha-Galaxy

Presented by BTG Specialty Pharmaceuticals

Speaker: Spencer Greene, MD, MS, FACEP, FACMT, FAACT, FAAEM

Dr. Greene will discuss pitfalls in the management of North American pit viper envenomation. In this lecture, you will learn how to avoid common mistakes when managing snakebite patients and gain a better understanding of the evidence to support best practices. Topics will include an overview of the medical management of envenomation with an emphasis on regional differences that may impact treatment decisions. 

2:30 pm - 3:15 pm

Rapid Objective Evaluation of Mild Head Injury in the ED Using EEG-Based Biomarkers

Presented by BrainScope Company, Inc.

Speakers: Marleine S. Clay, MD, FACEP

Computerized Tomography (CT) scan remains the standard of care for evaluating traumatic brain injury (TBI) in the Emergency Department (ED). Studies have reported that over 85% of head-injured patients receive CT scans in the ED, yet 91% of these scans are found to be negative. Not only does this practice expose these patients unnecessarily to radiation, but it also increases the use of this resource and lengthens throughput times in the ED. In addition, patients found to be CT negative are most often discharged without evaluation or referral for concussion. There is a great need for the integration of reliable, objective predictors of intracranial injury in the mild head injured population.

Join Dr. Marleine Clay as she examines the current challenges facing EDs today in assessing the mild head injured population and the impact BrainScope’s EEG-based biomarkers can have on improving care pathways and patient satisfaction. Prior to implementing BrainScope at INOVA Fairfax, Dr. Clay conducted a study to determine utilization, staff assessment, and patient experience of the BrainScope technology in daily use. Dr. Clay will review the results of the INOVA trial, which were overwhelmingly positive.